Our Programs


The first photosensitizer (PS) with long wavelength absorption near 800 nm and fluorescence above 830 nm for fluorescence-guided surgery and PDT of brain cancer.


Photobac-PDT has received Orphan Drug Designation for the treatment of glioblastoma (brain cancer)  from the United States FDA 

Approved IND of Photobac-PDT by the US FDA  for Phase I clinical trials of glioblastoma (brain cancer) at Roswell Park Comprehensive Cancer Center, Buffalo, NY.

Due  to its long wavelength absorption near 800 nm, the tumor cells present in margin and/or infiltrating cells deeply seated after fluorescence-guided surgery will also be destroyed after NIR PDT (longer the wavelength, deeper the tissue penetration).

In contrast to various porphyrin-based photosenitizers, Photobac shows limited skin phototoxicity.


An efficient nuclear Positron Emission Tomography (PET) imaging agent

After a successful pre-IND with FDA,  the IND is under submission and later a Phase I Clinical trial will be engaged.

Advantages of PET-ONCO ( I-124 analog):

Can be used for imaging a variety of tumors and metastases.

In contrast to F-18 FDG-PET, PET-ONCO can be used for imaging bladder, kidney, brain, pancreatic cancers.

Need ¼ of F-18 FDG dose for imaging tumors (from mice model studies)

Half-life: 4.2 days

For the production of PET imaging agent, cyclotrons are not required near the imaging facilities, which will make PET-imaging more economical.

Longer distance transportation is not an issue.


Single treatment and less expensive than chemotherapy.

If required, can be performed with other therapy (e.g. PDT & surgery, and PDT & Chemotherapy

Unlike the current FDA approved agent, does not show any significant photo-toxicity.

Easy to synthesize from chlorophyll, a natural product.

Can be used for fluorescence-guided PDT or surgery

Longer wavelength absorption (665nm) more than Photofrin

Photochlor obtained an Orphan Drug Designation (ODD) by FDA for Esophageal cancer

GMP material available for basic and clinical research


Photolitec has developed a portfolio of new nanoparticles capable of being used as a targeted drug delivery system.

Our nanoparticles are capable of carrying post-loaded imaging and chemotherapy agents


Photo-triggered release of    tumor-Imaging and therapy agents    (PDT and chemo-therapy) from lyophilized multi-functional    NPS.